Luspatercept - Acceleron Pharma/Celgene Corporation

Drug Profile

Luspatercept - Acceleron Pharma/Celgene Corporation

Alternative Names: ACE-536

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation
  • Class Antianaemics; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Beta-thalassaemia; Myelodysplastic syndromes
  • Phase II Anaemia; Myelofibrosis
  • No development reported Sickle cell anaemia

Most Recent Events

  • 27 Feb 2018 Acceleron and Celgene initiates the phase II BEYOND trial for Beta-thalassaemia in Greece (SC) (EudraCT2015-003225-33) (NCT03342404)
  • 28 Jan 2018 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA (SC)
  • 25 Jan 2018 Acceleron plans the phase III COMMANDS trial for Myelodysplastic syndromes (First-line therapy) in first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top